The new venture is backed by Biovance Capital, Torrey Pines Investment, and OrbiMed. Mondego Bio is advancing a portfolio of first- and best-in-class PTPN2 inhibitors designed to transform cancer ...
We’ll be honest. If you had told us a few decades ago we’d teach computers to do what we want, it would work some of the time, and you wouldn’t really be able to explain or predict exactly what it was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback